GlassScriptPhysician profile
Carlos A Lopez
NPI 1063531473
$1,579.55
in general payments reported to CMS, 2019-2025
15 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $124 · 2021: $165 · 2023: $550 · 2024: $309 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $264.59 | 2023-2024 | Prolaris |
| Novocure INC. | $216.40 | 2019-2025 | Optune, Optune Gio |
| Reflexion Medical, INC. | $213.00 | 2023 | Reflexion Medical Radiotherapy System |
| Varian Medical Systems, INC. | $185.08 | 2019-2021 | |
| Stryker Corporation | $135.12 | 2025 | Optablate |
| Elekta, INC. | $124.10 | 2020 | |
| Galvanize Therapeutics, INC | $102.90 | 2025 | Aliya System |
| Ge Healthcare | $101.76 | 2024 | |
| Siemens Medical Solutions USA, INC. | $53.69 | 2021 | |
| Merck Sharp & Dohme LLC | $44.60 | 2023 | Keytruda, Lynparza |
| Telix Pharmaceuticals | $41.13 | 2024-2025 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $39.46 | 2023-2024 | Imfinzi |
| Caris Mpi, INC. | $22.38 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $18.74 | 2025 | |
| Boston Scientific Corporation | $16.60 | 2024 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.